Jatuporn SujjitjoonElias SayourShih Ting TsaoMongkol UiprasertkulKleebsabai SanpakitJassada BuaboonnamPa thai YenchitsomanusLa ongsri AtchaneeyasakulLung Ji ChangSiriraj HospitalUniversity of FloridaUniversity of Florida College of MedicineUniversity of Electronic Science and Technology of ChinaShenzhen Geno-Immune Medical Institute2022-08-042022-08-042021-02-01Translational Oncology. Vol.14, No.2 (2021)193652332-s2.0-85097736239https://repository.li.mahidol.ac.th/handle/20.500.14594/76297A novel disialoganglioside 2 (GD2)-specific chimeric antigen receptor (CAR)-modified T cell therapy against retinoblastoma (RB) were generated. GD2-CAR consists of a single-chain variable fragment (scFv) derived from a monoclonal antibody, hu3F8, that is linked with the cytoplasmic signaling domains of CD28, 41BB, a CD3ζ, and an inducible caspase 9 death fusion partner. GD2 antigen is highly expressed in Y79RB cell line and in several surgical RB tumor specimens. In vitro co-culture experiments revealed the effective killing of Y79RB cells by GD2-CAR T cells, but not by control CD19-CAR T cells. The killing activities of GD2-CAR T cells were diminished when repeatedly exposed to the tumor, due to an attenuated expression of GD2 antigen on tumor cells and upregulation of inhibitory molecules of the PD1 and PD-L1 axis in the CAR T cells and RB tumor cells respectively. This is the first report to describe the potential of GD2-CAR T cells as a promising therapeutic strategy for RB with the indication of potential benefit of combination therapy with immune checkpoint inhibitors.Mahidol UniversityBiochemistry, Genetics and Molecular BiologyMedicineArticleSCOPUS10.1016/j.tranon.2020.100971